07:00 , Aug 27, 2015 |  BC Innovations  |  Product R&D

Bad actin

While many companies are looking beyond cytoskeletal inhibitors because of their high off-target toxicity, Novogen Ltd. has teased out a difference between normal and cancer cells in the way actin is regulated by tropomyosins. By...